Response to “NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors” by Xiang-Yu Meng

Related Posts

• NLRC5 germline variants as potential pharmacogenomic markers for immune checkpoint inhibitors

• Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary

  Background Cancer of unknown primary (CUP) is a heterogeneous group of metastatic cancers where a…

• Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma

  Background Loss of Ambra1 (autophagy and beclin 1 regulator 1), a multifunctional scaffold protein, promotes…